Neurogene Inc.
NASDAQ:NGNE · NASDAQ Global Market
+$0.76 today
Vol 0.28M · Avg 0.16M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
+83.10%
Period High
$34.37
Period Low
$14.95
Latest
$31.53
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
Alumis Inc. Common Stock
NASDAQ:ALMS
$2.83B
Solid Biosciences Inc.
NASDAQ:SLDB
$590.56M
Ocugen, Inc.
NASDAQ:OCGN
$429.92M
PureTech Health plc
NASDAQ:PRTC
$421.39M
Autolus Therapeutics plc
NASDAQ:AUTL
$407.20M
Benitec Biopharma Inc.
NASDAQ:BNTC
$314.96M
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
$304.14M
Quantum-Si incorporated
NASDAQ:QSI
$190.92M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$189.66M
ADC Therapeutics S.A.
NYSE:ADCT
$138.00M
What is the latest NGNE filing?
The latest filing shown is 3/A dated Jun 16, 2026.
How many recent filings does NGNE have?
Intrinsic Alpha currently shows 20 recent filings for NGNE.
Explore More
Continue the stock analysis
Jump to another research area for this company.